KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

ClearPoint Neuro (CLPT) Shares Outstanding (2017 - 2026)

ClearPoint Neuro's Shares Outstanding history spans 14 years, with the latest figure at $29.4 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 6.34% to $29.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.4 million, a 6.34% increase, with the full-year FY2025 number at $29.4 million, up 6.34% from a year prior.
  • Shares Outstanding hit $29.4 million in Q4 2025 for ClearPoint Neuro, up from $28.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding for CLPT hit a ceiling of $29.4 million in Q4 2025 and a floor of $20.7 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $25.3 million across 5 years, with a median of $24.6 million in 2023.
  • Biggest five-year swings in Shares Outstanding: soared 43.91% in 2021 and later grew 0.3% in 2023.
  • Tracing CLPT's Shares Outstanding over 5 years: stood at $23.7 million in 2021, then grew by 3.86% to $24.6 million in 2022, then rose by 0.3% to $24.7 million in 2023, then grew by 12.03% to $27.6 million in 2024, then increased by 6.34% to $29.4 million in 2025.
  • Business Quant data shows Shares Outstanding for CLPT at $29.4 million in Q4 2025, $28.4 million in Q3 2025, and $28.4 million in Q2 2025.